The treatments were well tolerated and safe. The quantitative mite count data were supported by the assessment of clinical signs associated with canine sarcoptic mange, and milbemycin oxime was shown to markedly reduce th e prevalence of these signs compared with their prevalence in vehicle-treated dogs.